Wegovy pill prescriptions exploded to 26,100 in its second week, smashing forecasts by 1,200% and rocketing Novo Nordisk’s stock 7% higher—but can this pill conquer the obesity epidemic before generics crash the party?
Story Highlights
- Wegovy oral pill launched January 5, 2026, hit 18,000+ prescriptions in week one, 26,100 in week two.
- Surpassed Bank of America’s 2026 weekly target of 2,000 prescriptions by over 13 times in week two alone.
- Novo Nordisk stock surged 7%, signaling investor bets on oral GLP-1s grabbing 25% of $95 billion market by 2030.
- Builds on injectable Wegovy’s 2024 record sales despite 2025 hurdles from cheaper compounded rivals.
Wegovy Pill Launch Shatters Early Expectations
Novo Nordisk launched the Wegovy pill, the first oral GLP-1 for weight loss, on January 5, 2026, in the U.S. IQVIA data shows over 18,000 prescriptions in the first week ending January 11. Week two, January 12-18, delivered 26,100 scripts.
This crushed Bank of America analysts’ full-year 2026 benchmark of roughly 2,000 weekly prescriptions, exceeding it 13-fold right out of the gate. The surge directly fueled a 7% jump in Novo Nordisk shares.
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance https://t.co/qMopInI5w6
— CNBC International (@CNBCi) May 6, 2026
Semaglutide Evolution from Needle to Pill
Semaglutide debuted in Novo Nordisk’s Ozempic injectable for diabetes in 2017. Off-label weight loss use boomed after 2021 trials. FDA approved Wegovy injectable for obesity in December 2021. Oral semaglutide arrived as Rybelsus for diabetes in 2019.
The Wegovy pill version, greenlit late 2025, targets patient preference for pills over injections amid chronic supply shortages. This format promises broader access in a market with over 1 billion obese adults worldwide.
2025 Headwinds Set Stage for 2026 Rebound
Compounded GLP-1 knockoffs hammered Novo Nordisk in 2025. Q1 sales for Ozempic hit nearly $5 billion and Wegovy $2.6 billion, but both dipped quarter-over-quarter.
Revenue grew 19% and operating profit 22% year-over-year, yet Novo cut 2025 forecasts: sales growth to 16-20%, profit to 4-7%. FDA victories curbed some compounders, but availability lingered.
The pill launch now counters this, validating CEO Lars Fruergaard Jørgensen’s push for oral dominance.
Injectable Wegovy posted record Q4 2024 sales of about 20 billion Danish kroner, or $2.9 billion. Full-year 2023 revenue reached $4.5 billion, with 2024 projections at $7.8 billion—a 73% jump.
Quarterly sales grew over eightfold from 2023 to 2024. Ozempic led with $13.9 billion in 2023, projected at $15.5 billion in 2024, holding 50% of the GLP-1 diabetes market.
Investor Optimism Fuels Massive Market Bets
Goldman Sachs projects oral GLP-1s like the Wegovy pill capturing 25% of a $95 billion total GLP-1 market by 2030. Bank of America saw the prescription surge as proof of concept.
Eli Lilly’s Zepbound injectable hit 25,000 prescriptions after one month, but Wegovy’s pill pace outstrips it early. Analysts expect Wegovy to double sales by 2027, overtaking Ozempic as Novo’s top earner before peaking in 2028-2029 amid generic threats.
Common sense favors innovation like pills that cut stroke and heart risks for 36% of U.S. adults with obesity.
Yet compounded cheapies expose regulatory gaps—FDA crackdowns align with protecting patients from unproven knockoffs. With 640 million diabetes patients by 2030 and 4 billion overweight globally by 2035, demand endures despite saturation risks post-2027.
Sources:
Semaglutide Sales Forecast: Revenue Projections Through 2030
First GLP-1 weight loss pill sales surge, giving Novo a market bump
Novo Nordisk: Wegovy sales by quarter 2025 – Statista
Novo cuts forecasts as compounded GLP-1s weigh on sales
Slowing Ozempic, Wegovy sales lead to cut in top end of Novo’s …
